Latest From Arthrex Inc.
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Legal experts testify that best option is for all decisions of the Patent Trial and Appeal Board to be reviewed by PTO director; House IP subcommittee wants to restrict ruling that PTAB judges were not constitutionally appointed.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Arthrex GMBH
- North America
- Parent & Subsidiaries
- Arthrex Inc.
- Senior Management
- Contact Info
Phone: (800) 933-7001
1370 Creekside Blvd.
Naples, FL 34108-1945
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.